Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment.

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

Quiver AI Summary Eisai Co., Ltd. and Biogen Inc. have provided an update on the regulatory review of their Alzheimer’s disease treatment, lecanemab, in the European Union.

At the time, Biogen and Eisai said they expected the European Commission, which generally follows the CHMP's advice, to make a final decision within 67 days, but the companies on Friday said the ...